Crispr Therapeutics

Crispr Therapeutics

Yahoo Finance • 20 days ago

Billionaire Ken Fisher Was Buying These 2 Cathie Wood Stocks

Q2 13F filings show that billionaire Ken Fisher's Fisher Asset Management opened new positions in CRISPR Therapeutics (NASDAQ: CRSP) and Coinbase Global (NASDAQ: COIN). Fisher's fund bought 77,960 CRISPR Therapeutics shares valued at abou... Full story

Yahoo Finance • 20 days ago

Autologous Hematopoietic Stem Cell Gene Therapy Market Global Report 2026: A $13.44 Billion Market by 2030 as Novartis, Vertex, CRISPR Therapeutics and Orchard Therapeutics Accelerate the Gene-Editing Race

Company Logo Boost ROI via rare-disease R&D, CRISPR therapies, scalable manufacturing, CDMO partnerships and regulatory incentives that accelerate approvals and commercialization. Autologous Hematopoietic Stem Cell Gene Therapy MarketAut... Full story

Yahoo Finance • 23 days ago

3 Reasons CRISPR Therapeutics Stock Is Still a Buy After a Rocky 2026

It's been a disappointing couple of years for shareholders of biotechnology outfit CRISPR Therapeutics (NASDAQ: CRSP). This stock's barely up since the end of 2022, lagging the broad market's gains. It's not the performance that investors... Full story

Yahoo Finance • 28 days ago

Cathie Wood Makes Striking Switch Between AI Stock Giants

This article first appeared on GuruFocus. Cathie Wood's Ark Invest made a sharp rotation across technology and biotechnology stocks last week, buying roughly $28 million of Meta Platforms (NASDAQ:META) while selling a nearly identical dol... Full story

Yahoo Finance • 29 days ago

Cathie Wood buys $27.9 million of surging megacap stock

Cathie Wood, head of Ark Investment Management, often buys her favorite tech stocks when she sees a new opportunity. That's what she did last week, pouring $27.9 million into Meta Platforms (META) as the company pushes deeper into AI. La... Full story

Yahoo Finance • 29 days ago

AbbVie vs. CRISPR Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?

Choosing between a mature pharmaceutical giant and a speculative gene-editing pioneer requires a clear understanding of your personal risk tolerance. Do you prefer AbbVie (NYSE:ABBV) or CRISPR Therapeutics (NASDAQ:CRSP) in 2026? AbbVie is... Full story

Yahoo Finance • 29 days ago

Amgen vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?

Choosing between Amgen (NASDAQ:AMGN) and Vertex Pharmaceuticals (NASDAQ:VRTX) requires balancing the stability of a diversified pharmaceutical giant against the high-growth, high-margin profile of a specialized biotechnology pioneer. Amge... Full story

Yahoo Finance • last month

Amgen vs. CRISPR Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?

Investors often face a choice between the stability of established giants and the high-stakes potential of clinical-stage innovators. Deciding between Amgen (NASDAQ:AMGN) and CRISPR Therapeutics (NASDAQ:CRSP) requires balancing immediate d... Full story

Yahoo Finance • last month

Axsome Therapeutics vs. CRISPR Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?

The healthcare sector is evolving as traditional drug development meets revolutionary gene editing. Investors are now choosing between Axsome Therapeutics (NASDAQ:AXSM) and CRISPR Therapeutics (NASDAQ:CRSP) for their medical portfolios. A... Full story

Yahoo Finance • last month

Rocket Pharmaceuticals (RCKT) Up 6% Since Last Earnings Report: Can It Continue?

A month has gone by since the last earnings report for Rocket Pharmaceuticals (RCKT). Shares have added about 6% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up to its next earnings releas... Full story

Yahoo Finance • last month

Where Will CRISPR Therapeutics Stock Be in 5 Years?

CRISPR Therapeutics (NASDAQ: CRSP) has already accomplished something most gene-editing companies are still trying to do: get a CRISPR-based medicine approved and onto the market. Now it has to prove it can build a business around the tech... Full story

Yahoo Finance • last month

Cathie Wood buys $3.5 million of surging tech stock

Cathie Wood, chief of Ark Investment Management, often adds to her favorite stocks when prices swing. This time, according to an email shared with TheStreet, she's buying $3.5 million of Robinhood stock, reversing her recent sales as the... Full story

Yahoo Finance • last month

Why Is CRISPR Therapeutics (CRSP) Up 7.1% Since Last Earnings Report?

It has been about a month since the last earnings report for CRISPR Therapeutics AG (CRSP). Shares have added about 7.1% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up to its next earning... Full story

Yahoo Finance • last month

Investors Shrug Off Good News for Heart Patients From New Meds

Impressive results came out on drugs from Amgen, Arrowhead Pharmaceuticals, and Crispr Therapeutics. Their shares are all lower this week. Continue Reading... Full story

Yahoo Finance • last month

Cathie Wood buys $53 million of popular semiconductor stock

Cathie Wood, chief of Ark Investment Management, often uses post-earnings swings to add to her favorite tech stocks. This week, she's buying more Nvidia, adding $53 million to her stake as the stock pulled back a day after surging on bett... Full story

Yahoo Finance • 2 months ago

Cathie Wood sells $4 million of surging AI stock

Cathie Wood, chief of Ark Investment Management, often trims her biggest winners after sharp rallies. This week, she's selling Tempus AI (TEM), taking some shares off the table after the healthcare AI stock surged nearly 30% in days and b... Full story

Yahoo Finance • 2 months ago

Biotech Breakout: What's in focus after Moderna's cancer win?

[mRNA or messenger RNA. The concept of mRNA vaccine. Innovative methods to treat virus. 3d render] Krot Studio INVESTORS SHOULD KNOW: A major Phase 3 trial win from Moderna (MRNA [https://seekingalpha.com/symbol/MRNA]) and Merck (MRK [htt... Full story

Yahoo Finance • 2 months ago

4 Gene-Editing Biotech Stocks Worth Watching for Long-Term Gains

Gene editing is emerging as a potentially transformative approach to medicine because it seeks to address disease at its genetic source rather than primarily managing downstream symptoms. Unlike conventional therapies that may require chro... Full story

Yahoo Finance • 2 months ago

Cathie Wood sells $11.6 million of surging tech stock

Cathie Wood, chief of Ark Investment Management, often locks in gains when her favorite tech stocks surge. That's what she's doing with Palantir Technologies (PLTR), trimming her position after the stock jumped more than 30% over the past... Full story

Yahoo Finance • 2 months ago

CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2026 Financial Results

ZUG, Switzerland and BOSTON, Aug. 03, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today reported financial results for the second quarter ended June 30, 2026. "The second quarter reflected strong execution across CRISPR... Full story